Royalty Pharma Reports Third Quarter 2023 Results
Drivers of total royalty receipts in the third quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).
- Drivers of total royalty receipts in the third quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).
- Royalty Pharma acquired the Spinraza royalty in the first quarter of 2023.
- In September 2023, Royalty Pharma acquired a royalty interest in Skytrofa from Ascendis Pharma A/S ( press release ) for an upfront payment of $150 million.
- During the third quarter of 2023, Royalty Pharma repurchased approximately five million shares for $144 million.